Moreover, because triple-negative breast cancer (TNBC), which is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, is an aggressive type of cancer that is difficult to treat, breast cancer patients suffer more if TNBC acquires radiotherapy resistance, and the patients do not survive after radiation therapy. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.